We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Events

08 Dec 2026 - 10 Dec 2026
25 Jan 2027 - 28 Jan 2027

AI Tool Enables In-Surgery Genomic Profiling of Brain Tumor for Real-Time Guidance

By HospiMedica International staff writers
Posted on 10 Jul 2023

Precise molecular diagnostics, which involve detailing DNA changes within a cell, can significantly influence a neurosurgeon's decision-making during surgery, such as the extent of brain tissue to be excised. More...

Over-removal in the case of less aggressive tumors can negatively impact a patient's neurological and cognitive functioning, while under-removal in the case of highly aggressive ones can leave malignant tissue behind, resulting in rapid growth and spread. Current intraoperative diagnostic methods involve brain tissue freezing and microscopic examination, but these techniques often distort cell appearance and compromise clinical assessment accuracy. Furthermore, the human eye, even with advanced microscopes, can fail to reliably identify subtle genomic variations on a slide. Now, a novel artificial intelligence (AI) approach addresses these issues.

Scientists at Harvard Medical School (Boston, MA, USA) have developed an AI tool capable of swiftly decoding a brain tumor's DNA to determine its molecular identity during surgery. This process can take several days or even weeks using traditional methods. Having immediate access to a tumor's molecular type helps neurosurgeons decide on the extent of brain tissue removal and the application of tumor-killing drugs directly into the brain, all while the patient is still on the operating table. Modern advances in genomics have enabled pathologists to distinguish molecular signatures and associated behaviors among various brain cancer types. Aggressive glioma, for instance, has three main subvariants, each bearing unique molecular markers and growth propensities. Although AI models have been developed to profile other cancer types (e.g., colon, lung, breast), gliomas present unique challenges due to their molecular complexity and vast variation in tumor cell morphology.

The newly developed tool, named CHARM (Cryosection Histopathology Assessment and Review Machine), significantly expedites molecular diagnostics, which can be particularly useful in regions with limited access to technology for quick cancer genetic sequencing. CHARM was developed using 2,334 brain tumor samples from 1,524 individuals with glioma from three distinct patient populations. The tool exhibited a 93% accuracy rate when identifying tumors with specific molecular mutations in an unseen set of brain samples, and it successfully classified three major types of gliomas with distinct molecular features. Moreover, the tool was adept at visually analyzing tissue surrounding malignant cells, identifying areas of greater cellular density and higher cell death rates, both of which are indicators of more aggressive glioma types.

Additionally, CHARM was able to detect clinically important changes in a subset of low-grade gliomas, a less aggressive glioma subtype that is less likely to invade surrounding tissue. The tool further linked cellular appearance with the molecular profile of the tumor, thereby enabling the algorithm to determine how a cell's appearance relates to the tumor's molecular type. This comprehensive assessment improves the model's accuracy and mirrors how a human pathologist would visually evaluate a tumor sample. While CHARM was initially trained and tested on glioma samples, the researchers believe it can be successfully retrained to identify other brain cancer subtypes. However, the tool would require periodic retraining to reflect new disease classifications as they emerge from new findings. Although CHARM is freely available to other researchers, it needs clinical validation through real-world testing and FDA clearance before it can be used in hospitals.

“Right now, even state-of-the-art clinical practice cannot profile tumors molecularly during surgery. Our tool overcomes this challenge by extracting thus-far untapped biomedical signals from frozen pathology slides,” said study senior author Kun-Hsing Yu, assistant professor of biomedical informatics in the Blavatnik Institute at HMS.

Related Links:
Harvard Medical School 


Gold Member
Blood Gas Analyzer
i-Check200
Hand-held Hemoglobin Analyzer
DiaSpect Tm
Pediatric Mask
Respire SOFT
Vessel Sealing Instrument
ERGOseal
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Artificial Intelligence

view channel
Image Credit: Shutterstock

Explainable AI Examines Sepsis Mortality Risk and Emergency Care Delays

Preventing sepsis-related deaths in emergency departments (EDs) remains challenging because patient deterioration can result from multiple rapidly evolving and interconnected factors. These include triage... Read more

Patient Care

view channel
Image: A view inside the custom virtual reality environment used in the study: a calm room with a teddy bear, soft colors and large windows looking out over the sea. (Image Credit: Walaa S. Abu Rukbah et al., Virginia Commonwealth University; CC-BY 4.0, https://creativecommons.org/licenses/by/4.0/)

Virtual Reality Program May Reduce Anxiety Before Pediatric Surgery

Presurgery anxiety affects an estimated 50% to 75% of children undergoing surgery and can complicate anesthesia induction, increase postoperative pain, and prolong recovery. Sedation is often used to manage... Read more

Medical Imaging

view channel
Image: A new automated approach could help predict which patients with dystonia will benefit from deep brain stimulation before surgery (Image Credit: Adobe Stock)

AI Uses Routine MRI to Predict Deep Brain Stimulation Response in Dystonia

Dystonia is a debilitating neurological movement disorder characterized by involuntary muscle contractions that cause abnormal movements and postures. Deep brain stimulation (DBS) is one of the few treatments... Read more

Health IT

view channel
Image Credit: Shutterstock

Telemonitoring Program Improves Quality of Life After Heart Failure Discharge

Heart failure is a chronic condition associated with high mortality, frequent hospitalizations, and reduced quality of life. Patients face particularly high risks of readmission and death after discharge,... Read more

Point of Care

view channel
Image: Jessica Ramella-Roman, professor of biomedical engineering at Florida International University, holding the PPRIM (Portable Preterm Imaging) device designed to detect early signs of preterm labor risk. (Photo courtesy of Florida International University)

Handheld Imaging Device May Help Identify Preterm Birth Risk Earlier

Preterm birth, defined as delivery before 37 weeks of pregnancy, can lead to serious neonatal complications, including neurological, developmental, and respiratory problems. However, identifying pregnancies... Read more

Business

view channel
Image: Stryker has acquired ZuriMED, adding the FiberLocker System, a rotator cuff augmentation technology designed to strengthen repairs, to its Sports Medicine portfolio. (Photo courtesy of ZuriMED)

Stryker Completes Acquisition to Broaden Shoulder Surgery Offerings

Stryker (Portage, MI, USA) has completed its acquisition of ZuriMED (Zurich, Switzerland), a privately held developer of the FiberLocker System, expanding its Sports Medicine portfolio with a commercialized... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.